Two US researchers claim they are close to a conclusive urine test for human growth hormone.
Don Catlin, a Los Angeles-based worldwide doping expert who oversaw blood testing for HGH at the Beijing Olympics, and Dr. Lance Liotta, a former pathology lab chief at the National Cancer Institute's Center for Cancer Research, have launched a study to build upon Liotta's ability to identify isolated markers of HGH in urine.
This is a groundbreaking step that'll change the game a bit," Catlin said Monday at a first-ever Growth Hormone Summit staged at the Beverly Hills Hotel.
Although baseball's union has maintained resistance to submitting players to HGH blood tests, the breakthrough has excited anti-doping and baseball officials who attended Monday's meeting.
Catlin's anti-doping research is entering the third year of work on a three-year, $450,000 grant by Major League Baseball to establish whether an HGH urine test is possible. He received identical funding from the NFL players' union.
Baseball officials who weren't allowed to discuss the situation publicly told The Los Angeles Times the Catlin-Liotta partnership now is poised to be "at the front of the line" when the Partnership for Clean Competition, consisting of Major League Baseball
(MLB), National Football League (NFL) and the U.S. Olympic Committee, begins to distribute funds from a pool of $10 million later this year.
Liotta, a professor at George Mason University, said he has arranged a study of students there that will analyze their natural HGH levels in blood and urine. The study will seek to establish a baseline standard that can be compared for instances when an abundance of synthetic HGH, prescribed mostly for AIDS patients and individuals with dwarfism, is found in the system.